Alpha 2.0
Login Register
» Authors » Steven Marx

Steven Marx

Explore the profile of Steven Marx including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 92
Followers 0
Related Specialties
General Surgery
Cardiology & Vascular Diseases
Nephrology
Top 10 Co-Authors
Stephen T Barclay
Samina Khan
Kristina Lohmann
Pietro Lampertico
Stefan Mauss
Amit Sharma
Michael Amdahl
Markus Ketteler
Zhenzhen Zhang
David Goldsmith
Published In
Adv Ther
Nephrol Dial Transplant
J Mol Cell Cardiol
EuroIntervention
Affiliations
Soon will be listed here.
Recent Articles
1.
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
Sardella G, Beerkens F, Dangas G, Cao D, Baber U, Sartori S, et al.
EuroIntervention . 2022 Aug; 18(11):e897-e909. PMID: 35979636
Background: Prior coronary artery bypass graft surgery (CABG) patients undergoing percutaneous coronary intervention (PCI) are often older and present with multiple comorbidities. Ticagrelor monotherapy after a short course of dual...
2.
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C
Sulkowski M, Cheng W, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N
Adv Ther . 2020 Nov; 38(1):423-440. PMID: 33145648
Introduction: Although hepatitis C virus (HCV) infection remains a major clinical, economic, and societal burden, the development of curative antiviral therapy may accelerate the path toward elimination. This analysis assessed...
3.
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Lampertico P, Mauss S, Persico M, Barclay S, Marx S, Lohmann K, et al.
Adv Ther . 2020 Sep; 37(11):4755-4756. PMID: 32915409
In the original article, there is an error in Fig. 1.
4.
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Lampertico P, Mauss S, Persico M, Barclay S, Marx S, Lohmann K, et al.
Adv Ther . 2020 Aug; 37(9):4033-4042. PMID: 32754824
Introduction: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week...
5.
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
Ketteler M, Martin K, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al.
Nephrol Dial Transplant . 2012 Mar; 27(8):3270-8. PMID: 22387567
Background: Optimal treatment for secondary hyperparathyroidism (SHPT) has not been defined. The IMPACT SHPT (ClinicalTrials.gov identifier: NCT00977080) study assessed whether dose-titrated paricalcitol plus supplemental cinacalcet only for hypercalcaemia is superior...
6.
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
Ketteler M, Martin K, Cozzolino M, Goldsmith D, Sharma A, Khan S, et al.
Nephrol Dial Transplant . 2011 Sep; 27(5):1942-9. PMID: 21931122
Background: Paricalcitol and cinacalcet are common therapies for patients on haemodialysis with secondary hyperparathyroidism (SHPT). We conducted a multi-centre study in 12 countries to compare the safety and efficacy of...
7.
Ion channel macromolecular complexes in the heart
Marx S
J Mol Cell Cardiol . 2003 Mar; 35(1):37-44. PMID: 12623298
The response to extracellular signals by ion channels requires the activity of several protein kinases and phosphatases to catalyze reversible phosphorylation/dephosphorylation events. The specificity of these events is governed in...